Will Noom go boom or bust in the GLP-1 era?

Jul 1, 2026

50:27

Digital Health & Health Tech Weight Management

Episode Description

When you look across the vast, ever-expanding GLP-1 landscape, you see a handful of key players with different services offered.

One of them is Noom, which attempts to differentiate itself from other telehealth shops by billing itself as a “behavior-change company.”

Simply put, Noom takes a lifestyle-based approach to weight loss, delving into the habits of its users and reorienting them towards healthier routines for diet and exercise. Building off that foundation, Noom then got into the GLP-1 prescription business in 2023.

Armed with a subscription-based health app and a substantial ad spend for campaigns featuring celebrity spokesperson Rebel Wilson, Noom has raised nearly $660 million over 10 funding rounds since its founding in 2008.

Yet like Weight Watchers, the company’s pivot in the age of GLP-1s hasn’t been without bumps along the way.

Noom conducted mass layoffs in 2022 and 2025 amid a slowdown in its key business units. Still, the company is trudging forward.

This week, Noom CEO Geoff Cook returns to the show to chat with reporter Bella Czajkowski about the company’s plans for the future, how the GLP-1 treatment space needs to evolve and what their go-forward advertising strategy is.

For our Trends segment, we’re talking about a pair of recent Supreme Court rulings – the ‘skinny label’ case between Hikma and Amarin as well as Bayer’s Roundup decision – and what they mean for the healthcare industry.

Ahead of our feature interview, you’ll hear from editorial director Jameson Fleming, who is back from his weeklong trip to cover Cannes. He’s got a full rundown of what you need to know about how medical marketing’s top work was received over there.